Conference Co-chairs:
Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, NC
Deborah F. DeLair, Northwell Health, Greenvale, NY
Douglas A. Levine, Merck Research Laboratories, Rahway, NJ

[R] Remote Presentation

Thursday, November 16

Registration
4:00 pm - 8:00 pm | Republic Foyer

Welcome and Education Session
Drs. Bae-Jump, DeLair and Levine
5:30 pm - 5:35 pm | Republic Ballroom
Not CME-eligible

Welcome and Introduction
5:30-5:32 Deborah F. DeLair, Northwell Health, Greenvale, NY
5:32-5:34 Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, NC

Education Session: Endometrial Cancer Basics
5:35 pm - 6:35 pm | Republic Ballroom
Session Chair: Douglas Levine (Merck)
CME-eligible

5:35-5:55 Pathology of endometrial cancer: the evolution from basic histology to the molecular era
Deborah F. DeLair, Northwell Health, Greenvale, NY

5:55-6:15 Management of newly diagnosed endometrial cancers and molecular classification
Douglas A. Levine, Merck Research Laboratories, Rahway, NJ

6:15-6:35 Navigating the complex world of adjuvant treatments and clinical trials
An AACR Special Conference in Cancer Research
Endometrial Cancer: Transforming Care Through Science
November 16-18, 2023 | Sheraton Boston Hotel | Boston, MA

Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, NC

Break
6:35 pm-6:45 pm | Republic Foyer

Opening Keynote Address
6:45 pm-7:30 pm | Republic Ballroom

6:45-6:47 \textbf{Introduction of Keynote Speaker}
Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, NC

6:47-7:30 \textbf{The Future of Endometrial Cancer Research: Possibility and Purpose}
Kemi M. Doll, University of Washington, Seattle, WA
\textit{CME-eligible}

Poster Session A / Reception
7:30 pm-9:00 pm | Back Bay C-D (2nd floor)

FRIDAY, NOVEMBER 17

Continental Breakfast
7:00 am-8:00 am | Back Bay C-D (2nd floor)

Plenary Session 1: Prevention and Screening
8:00 am-10:00 am | Republic Ballroom
\textit{Session Chair: Heather L. Hampel, City of Hope}
\textit{CME-eligible}

8:00-8:30 \textbf{New directions in prevention and early detection of endometrial cancers}
Megan A. Clarke, National Cancer Institute, Bethesda, MD

8:30-9:00 \textbf{Universal tumor screening for Lynch Syndrome versus germline multi-gene panel testing for all endometrial cancer patients}
Heather L. Hampel, City of Hope, Duarte, CA
9:00-9:30  The WID-qEC test for simple and accurate endometrial cancer detection  
Martin Widschwendter, University College London, London, UK

9:30-9:45  Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk*  
Tracy A. O'Mara, QIMR Berghofer Medical Research Institute, Brisbane QLD, Australia

9:45-10:00  Proteomic profiling of endometrial carcinomas*  
Dawn Cochrane, BC Cancer Cancer, Vancouver, BC, Canada

Break
10:00 am-10:20 am | Republic Foyer

Plenary Session 2: Disparities  
10:20 am-12:00 pm | Republic Ballroom  
Session Chair: Victoria L. Bae-Jump, University of North Carolina  
CME-eligible

10:20 -10:50  Racial disparities in guideline-concordant endometrial cancer treatment  
Ashely S. Felix, The Ohio State University, Columbus, OH

10:50 -11:20  Racial disparities in high grade endometrial cancers  
Michele L. Coté, Indiana University, Indianapolis, IN

Panel Discussion: Disparities  
11:20 am -12:00 pm | Republic Ballroom  
Moderator: Victoria L. Bae-Jump, University of North Carolina  
CME-eligible

11:20 -11:30  Lisa Barr, Uterine Task Force, Brooklyn, NY

11:30 -11:40  Neighborhood socioeconomic status and outcomes of patients with endometrial cancer  
Charlotte R. Gamble, MedStar Washington Hospital Center, Washington, D.C.

11:40-12:00  Panel Discussion with Q&A
Lunch on own
12:00 pm-2:00 pm

Plenary Session 3: Metabolic Liabilities
2:00 pm-4:00 pm | Republic Ballroom
Session Chair: Goutham Narla, University of Michigan
CME-eligible

2:00-2:30 

Targeting Obesity for Endometrial Cancer Treatment
Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, NC

2:30-3:00 

Understanding field carcinogenesis in obesity-related endometrial cancer
Ronald L. Chandler, Michigan State University, East Lansing, MI

3:00-3:30 

Therapeutic modulation of the serine/threonine phosphatase PP2A for the treatment of high grade endometrial cancers
Goutham Narla, University of Michigan, Ann Arbor, MI

3:30-4:00 

Unique metabolic changes in Lynch syndrome-associated endometrial cancer
Melinda S. Yates, University of North Carolina, Chapel Hill, NC

Break
4:00 pm-4:20 pm | Republic Foyer

Plenary Session 4: Targeted Therapeutics
4:20 pm-6:20 pm | Republic Ballroom
Session Chair: Rugang Zhang, MD Anderson Cancer Center
CME-eligible

4:20-4:50 

Personalized adjuvant treatment in endometrial cancer
Tjalling Bosse, Leiden University Medical Center, Leiden, Netherlands

4:50-5:20 

Epigenetic approaches to endometrial cancer
Rugang Zhang, MD Anderson Cancer Center, Houston, TX

5:20-5:50 

Molecular diversity of uterine serous carcinoma
Alessandro D. Santin, Yale University, New Haven, CT
5:50 - 6:05

The Combination of the Glucagon Like Peptide-1 Receptor Agonist Semaglutide and the Progestin Levonorgestrel is Highly Effective in Preclinical Studies of Endometrial Cancer*

Kimberly K. Leslie, The University of New Mexico, Albuquerque, NM

6:05 - 6:20

CD73 is a novel repressor of mutant β-catenin oncogenic activity in endometrial cancer*

Rebecca M. Hirsch, University of North Carolina Chapel Hill, Chapel Hill, NC

Poster Session B / Reception
6:30 pm-8:00 pm | Back Bay C-D (2nd floor)

SATURDAY, NOVEMBER 18

Continental Breakfast
7:00 am-8:00 am | Back Bay C-D (2nd floor)

Plenary Session 5: Immune Landscape
8:00 am-10:00 am | Republic Ballroom

Session Chair: Deborah F. DeLair, Northwell Health
CME-eligible

8:00-8:30

Spontaneous humoral responses in endometrial cancer provide a rationale for novel tumor-penetrating therapeutic antibodies

Jose R. Conejo-Garcia, Duke University, Durham, NC

8:30-9:00

Strategies to overcome immunotherapy resistance in endometrial cancer [R]

Haider S. Mahdi, University of Pittsburgh, Pittsburgh, PA

9:00-9:30

Recent Therapeutic Advancements in Advanced Endometrial Cancer [R]

Vicky Makker, Memorial Sloan Kettering Cancer Center, New York, NY

9:30-9:45

Patients with endometrial cancer and benign gynecologic conditions exhibit unique vaginal and rectal microbiomes*

Nicole R. Jimenez, University of Arizona, Phoenix, Arizona
9:45-10:00   ARID1A/B mutations retarget mSWI/SNF chromatin remodeler activity and define a spectrum of dedifferentiation in endometrial carcinoma*
Jessica D. St. Laurent, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA

Break
10:00 am-10:20 am | Republic Foyer

Plenary Session 6: Molecular Mechanisms
10:20 am-12:20 pm | Republic Ballroom
Session Chair: Jessica L. Bowser, University of North Carolina
CME-eligible

10:20-10:50    Improving response to therapies: from bench molecular mechanisms to clinical trial design
Katherine Fuh, University of California San Francisco, San Francisco, CA

10:50-11:20    Novel genomic features of POLE-mutant tumors: the utility for tumor classification and identification of new driver alleles
Polina Shcherbakova, University of Nebraska Medical Center, Omaha, NE

11:20-11:50    Harnessing the unique biology of CD73 for improving endometrial cancer outcomes
Jessica L. Bowser, University of North Carolina, Chapel Hill, NC

11:50-12:05    Patient derived organoid as a model to study estrogen mediated endometrial cancer*
Breanna M.W. Jeffcoat, University of North Carolina Chapel Hill, Chapel Hill, NC

12:05-12:20    Location, location, location: Why cellular localization of mutant β-catenin matters in endometrial cancer*
Molly L. Parrish, University of North Carolina Chapel Hill, Chapel Hill, NC

Closing Remarks
12:20 pm-12:30 pm
Douglas A. Levine, Merck Research Laboratories, Rahway, NJ